Prognostic role and characteristics of the indeterminate response in differentiated thyroid cancer: a systematic review
- PMID: 38265607
- DOI: 10.1007/s12020-024-03688-5
Prognostic role and characteristics of the indeterminate response in differentiated thyroid cancer: a systematic review
Abstract
Purpose: The management of differentiated thyroid cancer (DTC) is actually based on a dynamic risk stratification based on classes of response to the therapy. Indeterminate response (IR) includes a heterogeneous group of patients with different characteristics, particularly different Tg and AbTg levels and/or imaging findings. The aim of systematic review (SR) is to evaluate the prognosis, diagnostic findings and other characteristics of patients in the IR class.
Methods: A wide literature search in the Scopus, PubMed/MEDLINE and Web of Science databases was performed to find published articles on patients with DTC and IR after treatment. The quality assessment of studies was carried out using QUADAS-2 evaluation.
Results: Eight articles were included in the systematic review. Six studies evaluated the prognosis and the prognostic factor in patients with IR, one study evaluated the role of 2-[18F]FDG PET-CT in the management of patients with IR and biochemical incomplete response and one study the risk factors for IR.
Conclusion: Patients with DTC and IR to therapy have a probability of disease relapse < 15%. Tg value could be a predictor of disease progression. The role of 2-[18F]FDG PET-CT needs to be further investigated.
Keywords: Indeterminate response; Systematic review; Thyroid cancer.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- D. Albano, F. Dondi, P. Bellini, F. Bertagna, Biomarkers and Molecular Imaging in Postoperative DTC Management. In: Giovanella, L. (eds) Integrated Diagnostics and Theranostics of Thyroid Diseases (Springer, Cham, 2023), https://doi.org/10.1007/978-3-031-35213-3_8
-
- M.E. Cabanillas, D.G. McFadden, C. Durante, Thyroid cancer. Lancet 388(10061), 2783–2795 (2016). https://doi.org/10.1016/S0140-6736(16)30172-6 - DOI - PubMed
-
- S. Filetti, C. Durante, D. Hartl, S. Leboulleux, L.D. Locati, K. Newbold, M.G. Papotti, A. Berruti, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann. Oncol. 30(12), 1856–1883 (2019). https://doi.org/10.1093/annonc/mdz400 - DOI - PubMed
-
- E.F.S. van Velsen, R.P. Peeters, M.T. Stegenga, F.J. van Kemenade, T.M. van Ginhoven, M. van Balkum, F.A. Verburg, W.E. Visser, Evaluating Disease-specific Survival Prediction of Risk Stratification and TNM Systems in Differentiated Thyroid Cancer. J. Clin. Endocrinol. Metab. 108(6), e267–e274 (2023). https://doi.org/10.1210/clinem/dgac721 - DOI - PubMed
-
- B.R. Roman, L.G. Morris, L. Davies, The thyroid cancer epidemic, 2017 perspective. Curr. Opin. Endocrinol. Diabetes Obes. 24(5), 332–336 (2017). https://doi.org/10.1097/MED.0000000000000359 - DOI - PubMed - PMC
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
